Two new drugs, approved by the FDA in 2023, are now available for the treatment of myasthenia gravis (MG).
Newly Approved Myasthenia Gravis Medications
Here's a breakdown of these new treatments:
- Rozanolixizumab-noli (Rystiggo): This is the first approved treatment specifically for both anti-acetylcholine receptor and anti-muscle-specific kinase antibody-positive myasthenia gravis.
- It works by targeting the underlying cause of MG by reducing the harmful antibodies that attack the neuromuscular junction.
- It represents a significant advancement for individuals with both of these common subtypes of MG.
- Zilucoplan (Zilbrysq): This drug is notable as the first MG treatment approved for self-administration through a daily injection.
- This offers patients a more convenient and manageable treatment option.
- It also provides an alternative therapeutic approach to manage MG symptoms.
Table of New MG Drugs
| Drug Name | Brand Name | Type of MG Treated | Administration | Key Feature |
|---|---|---|---|---|
| Rozanolixizumab-noli | Rystiggo | Anti–acetylcholine receptor and anti–muscle-specific kinase antibody-positive | Intravenous infusion | First drug approved for both antibody types. |
| Zilucoplan | Zilbrysq | General MG | Daily self-injection | First MG treatment for self-administration by daily injection. |
These new treatments offer additional options for managing the symptoms of myasthenia gravis, potentially improving the quality of life for many patients.
